» Articles » PMID: 33854085

Validation of Three Predictive Models for Suboptimal Cytoreductive Surgery in Advanced Ovarian Cancer

Overview
Journal Sci Rep
Specialty Science
Date 2021 Apr 15
PMID 33854085
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The standard treatment for advanced ovarian cancer (AOC) is cytoreduction surgery and adjuvant chemotherapy. Tumor volume after surgery is a major prognostic factor for these patients. The ability to perform complete cytoreduction depends on the extent of disease and the skills of the surgical team. Several predictive models have been proposed to evaluate the possibility of performing complete cytoreductive surgery (CCS). External validation of the prognostic value of three predictive models (Fagotti index and the R3 and R4 models) for predicting suboptimal cytoreductive surgery (SCS) in AOC was performed in this study. The scores of the 3 models were evaluated in one hundred and three consecutive patients diagnosed with AOC treated in a tertiary hospital were evaluated. Clinicopathological features were collected prospectively and analyzed retrospectively. The performance of the three models was evaluated, and calibration and discrimination were analyzed. The calibration of the Fagotti, R3 and R4 models showed odds ratios of obtaining SCSs of 1.5, 2.4 and 2.4, respectively, indicating good calibration. The discrimination of the Fagotti, R3 and R4 models showed an area under the ROC curve of 83%, 70% and 81%, respectively. The negative predictive values of the three models were higher than the positive predictive values for SCS. The three models were able to predict suboptimal cytoreductive surgery for advanced ovarian cancer, but they were more reliable for predicting CCS. The R4 model discriminated better because it includes the laparotomic evaluation of the peritoneal carcinomatosis index.

Citing Articles

Neglected Anatomical Areas in Ovarian Cancer: Significance for Optimal Debulking Surgery.

Kostov S, Selcuk I, Watrowski R, Dineva S, Kornovski Y, Slavchev S Cancers (Basel). 2024; 16(2).

PMID: 38254777 PMC: 10813817. DOI: 10.3390/cancers16020285.


Should We Abandon Intraperitoneal Chemotherapy in the Treatment of Advanced Ovarian Cancer? A Meta-Analysis.

Climent M, Serra A, Balaguer C, Llueca A J Pers Med. 2023; 13(12).

PMID: 38138863 PMC: 10745120. DOI: 10.3390/jpm13121636.


"Things Have Changed"-Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients.

Ceccaroni M, Roviglione G, Bruni F, Dababou S, Venier M, Zorzi C Cancers (Basel). 2023; 15(24).

PMID: 38136272 PMC: 10741886. DOI: 10.3390/cancers15245726.


Surgery in Recurrent Ovarian Cancer: A Meta-Analysis.

Climent M, Serra A, Llueca M, Llueca A Cancers (Basel). 2023; 15(13).

PMID: 37444580 PMC: 10340282. DOI: 10.3390/cancers15133470.


A machine-learning-based prediction of non-home discharge among acute heart failure patients.

Okada A, Kaneko H, Konishi M, Kamiya K, Sugimoto T, Matsuoka S Clin Res Cardiol. 2023; 113(4):522-532.

PMID: 37131097 PMC: 10955024. DOI: 10.1007/s00392-023-02209-0.


References
1.
Chi D, Eisenhauer E, LANG J, Huh J, Haddad L, Abu-Rustum N . What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol. 2006; 103(2):559-64. DOI: 10.1016/j.ygyno.2006.03.051. View

2.
Deffieux X, Castaigne D, Pomel C . Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer. 2006; 16 Suppl 1:35-40. DOI: 10.1111/j.1525-1438.2006.00323.x. View

3.
Bristow R, Duska L, Lambrou N, Fishman E, ONeill M, Trimble E . A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000; 89(7):1532-40. DOI: 10.1002/1097-0142(20001001)89:7<1532::aid-cncr17>3.0.co;2-a. View

4.
Feng Z, Wen H, Jiang Z, Liu S, Ju X, Chen X . A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. J Gynecol Oncol. 2018; 29(5):e65. PMC: 6078898. DOI: 10.3802/jgo.2018.29.e65. View

5.
Sugarbaker P, Jablonski K . Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995; 221(2):124-32. PMC: 1234945. DOI: 10.1097/00000658-199502000-00002. View